Zenocutuzumab OK’d for NRG1 Fusion-Positive Cholangiocarcinoma M. Alexander Otto, PA, MMSc May 11, 2026

https://www.medscape.com/viewarticle/zenocutuzumab-okd-nrg1-fusion-positive-cholangiocarcinoma-2026a1000f2r The FDA has approved zenocutuzumab (BIZENGRI, Partner Therapeutics) for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring an NRG1 gene fusion following progression on or after prior systemic therapy.